Laryngeal squamous cell carcinoma (LSCC) is the second most common head and neck cancer in the world (1). The incidence of LSCC in China has exhibited an increasing trend in the young population (2,3). LSCC is a complex disease, and it is hypothesized that both genetic and environmental factors play a role in it (4). Epigenetic modifications, including DNA methylation, are known as the bridging factors of genetics and the environment (5). However, the role of epigenetic modifications in the pathogenesis and progression of LSCC remains to be explained.

DNA methylation of CpG islands (CGIs) is a significant regulatory mechanism of gene expression (6). Epigenetic silencing of tumor suppressor genes by promoter hypermethylation is considered to be a significant event in the progression of cancers including leukemia (7), lung cancer (8) and prostate cancer (9). Gene-body methylation levels are also demonstrated to be correlated with gene expression (10,11).

TGFB2 is a member of the transforming growth factor β (TGFB) family, which encodes multifunctional peptides in the regulation of cell proliferation, differentiation, adhesion and migration (12). TGFB is able to inhibit tumor growth at the early stages and promote tumor growth at the late stages of disease (13). A previous study has demonstrated that increased TGFB2 promoter methylation level is associated with prostate cancer progression (14). BCL2L11 encodes a member of the BCL-2 (B cell lymphoma 2) protein family, which acts as an apoptotic activator that is involved in a wide variety of cellular activities (15). BCL2L11 methylation has been noted to be associated with the risk of hematological and epithelial cancers (16).

In the current study, the methylation levels of TGFB2 and BCL2L11 were investigated in male laryngeal cancer patients to determine whether these epigenetic markers are associated with LSCC risk.

In the present study, we assessed the TGFB2 and BCL2L11 methylation levels in LSCC and their adjacent non-neoplastic tissues using bisulfite pyrosequencing technology. As shown in Fig. 1, the tested fragments were located in the CGIs of the TGFB2 promoter (chr1:218519058-218519113) and BCL2L11 gene-body (chr2:111879764-111879817). A total of eight and six CpG dinucleotides were measured for TGFB2 and BCL2L11, respectively. The mean methylation levels of the tested CpG sites were used to compare their differences between the LSCC tumor and the adjacent normal tissues.

Our results revealed that there were no statistically significant differences of the methylation levels of TGFB2 promoter (Fig. 2, P=0.653) and BCL2L11 gene-body (Fig. 3, P=0.311) between LSCC tissues and the paired normal tissues. Further tests demonstrated no change in the results when adjusted for age, smoking history, histological differentiation and clinical stage (all adjusted P>0.05). Moreover, there was no difference in the TGFB2 promoter or BCL2L11 gene-body methylation levels between tumor tissues and paired normal tissues in the breakdown analyses by age, smoking history, histological differentiation or clinical stage of the patients (Figs. 2 and 3, all P>0.05, data not shown).

The aim of the present study was to determine whether DNA methylation of the TGFB2 promoter and BCL2L11 gene-body was associated with LSCC risk. Through a series of statistical analyses of these two genes, no clear correlation with laryngeal cancer was observed. Further subgroup tests by age, smoking history, histological differentiation and clinical stage also produced similar results.

Epigenetic modifications are central to tumorigenesis (18). In cancer cells, global hypomethylation is accompanied by hypermethylation of certain gene promoter CGIs (6). DNA methylation of the gene promoter region leads to gene silencing by blocking the binding of transcription factors or methyl-binding proteins (6), while a positive correlation has been observed in a variety of human tissue types between gene-body methylation and gene expression (10,19). As for LSCC, aberrant DNA methylation of tumor suppressor genes, including MGMT, CHD5, p16, p14, PTEN, MYCT1 and FHIT, has been reported (4,20–23). DNA methylation levels of the promoter and gene-body are relatively dynamic (24). However, there are no previous studies on gene-body methylation in LSCC.

TGFB2 promoter hypermethylation was first identified as a potential epigenetic marker of prostate cancer in whole genome methylation profiling studies (25). A previous study revealed that the gene suppression of TGFB2 was not associated with DNA methylation but with chromatin remodeling in breast cancer tissue samples (26). In the present study, we did not observe any association between TGFB2 methylation and LSCC, suggesting that there were other genetic or epigenetic modifications in LSCC.

The apoptosis-related gene BCL2LL1 has been noted to be hypermethylated in colon cancer (27), hematological and epithelial cancers (16). In addition, low BCL2L11 expression in chronic myeloid leukemia was ascribed to BCL2LL1 hypermethylation at the gene promoter (28). Due to the limitation of not identifying a suitable primer set to assess the promoter CGI of the BCL2LL1 gene, we selected the CGI in the gene-body region as an alternative. Although our study did not identify any significant association with BCL2L11 gene-body methylation, the contribution of other CGIs to LSCC risk remains to be explored.

In conclusion, our study suggests a lack of contribution of the TGFB2 promoter and BCL2L11 gene-body methylation to LSCC in male patients. However, this study was designed as a pilot study, and further investigations are required to confirm our findings.